- |||||||||| dalfampridine / Generic mfg.
Trial initiation date, Trial termination, Trial primary completion date: Fampridine Pregnancy Exposure Registry (clinicaltrials.gov) - Nov 25, 2015 P=N/A, N=375, Terminated, Not yet recruiting --> Recruiting Initiation date: Dec 2015 --> Aug 2015 | Recruiting --> Terminated | Trial primary completion date: Oct 2020 --> Dec 2015; Due to low enrollment, registration closed in agreement with the Regulatory Agency
- |||||||||| dimethyl fumarate / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date, Adverse events: Tecfidera Slow-titration Study (clinicaltrials.gov) - Nov 24, 2015 P3, N=62, Terminated, Active, not recruiting --> Completed N=300 --> 62 | Recruiting --> Terminated | Trial primary completion date: Mar 2017 --> Dec 2015; Sponsor decision
- |||||||||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial termination: REGAIN: A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®) (clinicaltrials.gov) - Nov 22, 2015 P3, N=11, Terminated, Trial primary completion date: Jan 2020 --> Apr 2016 Completed --> Terminated; Cancelled due to low enrollment
- |||||||||| New trial: Accu-Chek (clinicaltrials.gov) - Nov 21, 2015
P=N/A, N=200, Not yet recruiting,
- |||||||||| Trial completion: The CARRA Registry (clinicaltrials.gov) - Nov 17, 2015
P=N/A, N=9587, Completed, Trial primary completion date: Feb 2014 --> Dec 2015 Enrolling by invitation --> Completed
- |||||||||| dimethyl fumarate / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: INSPIRE: BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Nov 16, 2015 P3, N=58, Terminated, Active, not recruiting --> Terminated; The ASCEND Study did not achieve statistical significance on the primary or secondary endpoints. N=1170 --> 58 | Recruiting --> Terminated | Trial primary completion date: Jun 2019 --> Feb 2016; Sponsor Decision
- |||||||||| leucovorin calcium / Generic mfg.
Trial termination, Trial primary completion date: A Folinic Acid Intervention for Autism Spectrum Disorders (clinicaltrials.gov) - Nov 15, 2015 P2, N=160, Terminated, Active, not recruiting --> Completed Suspended --> Terminated | Trial primary completion date: Sep 2017 --> Jun 2015; Non-compliance
- |||||||||| DegludecPlus (insulin degludec/insulin aspart) / Novo Nordisk
Trial initiation date, Trial primary completion date: Post Marketing Surveillance (PMS) Study of Ryzodeg (clinicaltrials.gov) - Nov 14, 2015 P=N/A, N=1000, Not yet recruiting, Recruiting --> Active, not recruiting Initiation date: Apr 2015 --> Dec 2015 | Trial primary completion date: Mar 2016 --> Sep 2017
- |||||||||| Trial primary completion date: CLaRA: Curcuma Longa L in Rheumatoid Arthritis (clinicaltrials.gov) - Nov 14, 2015
P1, N=45, Not yet recruiting, Initiation date: Apr 2015 --> Dec 2015 | Trial primary completion date: Mar 2016 --> Sep 2017 Trial primary completion date: Jan 2017 --> Jun 2017
|